Corporate Profile
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. We developed and are commercializing KOMZIFTI™ (ziftomenib), an FDA-approved menin inhibitor, and we continue to advance our menin inhibition and farnesyl transferase inhibition programs.
Events
-
03-12-2026 at 9:00 AM EDT
-
03-10-2026 at 10:40 AM EDT
-
03-05-2026 at 8:00 AM EST
-
03-04-2026 at 11:50 AM EST